Glioblastoma multiforme (GBM) is a highly aggressive brain cancer that is characterized by the paradoxical features of intense apoptosis resistance yet a marked propensity to undergo necrosis. Bcl2L12 (for Bcl2-Like12) is a nuclear and cytoplasmic oncoprotein that is universally overexpressed in primary GBM and functions to block postmitochondrial apoptosis signaling by neutralizing effector caspase-3 and caspase-7 maturation. This postmitochondrial block in apoptosis engenders the alternate cell fate of cellular necrosis, thus providing a molecular explanation for GBM's classical features. Whereas Bcl2L12-mediated neutralization of caspase-7 maturation involves physical interaction, the mechanism governing Bcl2L12-mediated inhibition of caspase-3 activity is not known. The nuclear localization of Bcl2L12 prompted expression profile studies of primary astrocytes engineered to overexpress Bcl2L12. The Bcl2L12 transcriptome revealed a striking induction of the small heat shock protein ␣-basic-crystallin (␣B-crystallin/HspB5), a link reinforced by robust ␣B-crystallin expression in Bcl2L12-expressing orthotopic glioma and strong coexpression of ␣B-crystallin and Bcl2L12 proteins in human primary GBMs. On the functional level, enforced ␣B-crystallin or Bcl2L12 expression enhances orthotopic tumor growth. Conversely, RNAi-mediated knockdown of ␣B-crystallin in Bcl2L12-expressing astrocytes and glioma cell lines with high endogenous ␣B-crystallin showed enhanced apoptosis, yet decreased necrotic cell death with associated increased caspase-3 but not caspase-7 activation. Mirroring this specific effect on effector caspase-3 activation, ␣B-crystallin selectively binds procaspase-3 and its cleavage intermediates in vitro and in vivo. Thus, ␣B-crystallin is a Bcl2L12-induced oncoprotein that enables Bcl2L12 to block the activation of both effector caspases via distinct mechanisms, thereby contributing to GBM pathogenesis and its hallmark biological properties.
G
lioblastoma multiforme (GBM) is a highly aggressive brain cancer characterized by rapid tumor cell proliferation, intense apoptosis resistance, and marked necrosis, tumor biological features underlying its neurologically destructive course and its high lethality typically within 12-24 months of diagnosis. The mechanisms underlying GBM's intense apoptosis resistance and associated poor therapeutic responsiveness relate in part to the reinforcing activities of coactivated RTKs (1) and defective PTEN and p53 proteins (2, 3) and modulation of classical apoptosis regulators such as Bcl-2 family proteins (4-7), soluble decoy receptor 3 (DcR3) (8) , APRIL (9) , and PEA-15 (10) (11) (12) .
In GBM oncogenomic studies, we identified and functionally characterized Bcl2L12 (for Bcl2-Like-12), a proline-rich and BH2 domain-containing protein that is robustly expressed in virtually all human primary GBM specimens (13) . Enforced Bcl2L12 expression in primary cortical astrocytes conferred marked apoptosis resistance and engendered cellular necrosis through inhibition of effector caspase-3 and caspase-7 maturation downstream of mitochondria (13) . The capacity of Bcl2L12 to block caspase-7 activation matched well with direct physical interaction in vitro and in vivo with the pro-caspase. The means through which Bcl2L12 inhibited caspase-3 was not defined and did not involve physical interaction between Bcl2L12 and caspase-3.
In this study, we sought to elucidate the mechanism of Bcl2L12-mediated neutralization of caspase-3. Transcriptome analyses of Bcl2L12-expressing astrocytic cultures revealed prominent upregulation of ␣B-crystallin expression. The previously described capacity of recombinant ␣B-crystallin protein to inhibit caspase-3 activation in a cell-free system (14) prompted a detailed analysis of a potential Bcl2L12-␣B-crystallin signaling axis in cultured astrocytes and glioma cell lines, orthotopic glioma xenotransplants, and primary GBM specimens. Gain-and loss-of-function assays and detailed biochemical studies in both normal and neoplastic glial model systems establish a pathway comprised of Bcl2L12-␣B-crystallin-caspase-3 in the regulation of apoptosis and necrosis in vitro and in vivo. Together, these studies reveal the multifunctional nature of the Bcl2L12 oncoprotein, operating in both the cytoplasm and nucleus to effect survival signaling in gliomagenesis.
Results
Bcl2L12 Drives Up-Regulation of ␣B-Crystallin. The cytoplasmic presence of Bcl2L12 is consistent with its physical and inhibitory actions on caspase-7 (13) . At the same time, abundant Bcl2L12 in the nucleoplasm prompted transcriptional profiling studies to assess whether the range of Bcl2L12's antiapoptotic activities might extend to more direct effects on gene expression. Strikingly, Bcl2L12 V5 -expressing Ink4a/Arf-deficient cortical astrocytes showed marked up-regulation of ␣B-crystallin by micorarray, quantitative RT-PCR, and Western blot analyses [ Fig. 1A , supporting information (SI) Table S1 , and data not shown]. In contrast, ␣B-crystallin was unchanged in the context of Bcl-2 expression (Fig.  1 A) , suggesting that up-regulation of ␣B-crystallin is not a general function of Bcl-2 family proteins. The specific physiological link between Bcl2L12 and ␣B-crystallin is supported further by the inability of Bcl2L12 to influence expression of other apoptosis modulators including postmitochondrial caspases and their inhibitors and other members of the heat shock protein family such as Hsp70 and Hsp27 ( Fig. 1 A and Table S1 ). Table S2 provides a complete list of differentially expressed genes by 1.3-fold relative to empty vector controls.
To assess whether Bcl2L12 V5 -dependent up-regulation of ␣B-crystallin in cell culture is also operative in glioma cells in vivo, we examined ␣B-crystallin protein expression in intracranial xenotransplants derived from the well established U87MG human glioma model system. Bcl2L12 V5 and EGFRvIII overexpression resulted in reduced survival of SCID mice after intracerebral orthotopic injection with ID 50 values of 36 days (pBabe), 31 days (Bcl2L12 V5 ; P ϭ 0.043 vs. pBabe), and 29 days (EGFRvIII; P ϭ 0.001 vs. pBabe) (Fig. S1 A) . These Bcl2L12 V5 -transduced tumors exhibited increased anti-␣B-crystallin immunoreactivity relative to pBabe-transduced controls (Fig. 1B and Fig. S1B ), whereas Hsp27 protein levels remain unchanged in Bcl2L12-driven and control xenografts (Fig. S1B ). These experimental observations were consistent with quantitative RT-PCR (Fig. S2 A) and immunohistochemistry (IHC) (Fig. S2B) analyses of primary human GBM. Specifically, using a well characterized highly specific anti-␣B-crystallin mAb, we detected strong ␣B-crystallin signal in 41 of 47 primary and 3 of 6 secondary GBM samples (Fig. S2B for representative cores). ␣B-crystallin staining is restricted to tumor cells without demonstrable positivity in endothelial cells of the tumor vasculature (Fig. S2B) .
Our previous work established that Bcl2L12 is robustly expressed in Ͼ90% of human primary GBM specimens by IHC-tissue microarray (TMA) analysis (13) . To examine further possible Bcl2L12-␣B-crystallin coexpression, we used iCys laser scanning cytometry technology in IHC-TMA analyses (see SI Methods for detailed staining protocol and analysis methodology). Triply stained for Bcl2L12 [diaminobenzidine (DAB), brown], ␣B-crystallin (FastRed), and hematoxylin, TMA sections were scanned with three lasers in distinct wavelength channels, demonstrating the coexpression of both proteins (Fig. 1C) . Heat maps and density plots of representative primary GBM cores with high and low ␣B-crystallin expression revealed that all ␣B-crystallin overexpressing tumor cells are also positive for Bcl2L12 (Fig. 1D) . Analysis of Bcl2L12 and ␣B-crystallin distribution across 61 GBM cores revealed significant correlation between Bcl2L12 and ␣B-crystallin expression ( ϭ 0.62; Fig. 1E ). Coexpression of both proteins was confirmed further by intensity profiles of single tumor cells, documenting that highest Bcl2L12 expression coincided with highest ␣B-crystallin expression (Fig. S3) . Together, these multilevel expression studies suggest an association between Bcl2L12 and ␣B-crystallin expression in primary and transformed glial cells in vitro and in experimental models and primary tumors in vivo.
␣B-Crystallin Is Antiapoptotic and Protumorigenic in Human Glioma
Cells in Vitro and in Vivo. To explore the cancer biological relevance of ␣B-crystallin, we monitored apoptosis signaling upon knockdown of ␣B-crystallin or other apoptosis inhibitors operating at the mitochondrial (e.g., Bcl-2) or postmitochondrial levels (e.g., Bcl2L12 and XIAP). We selected LN235 glioma cells on the basis of high endogenous Bcl2L12 and ␣B-crystallin expression. After verification of knockdown for the specific proteins ( Fig. 2A) , Western blot analysis of effector caspase activation profiles revealed a predominant increase in active caspase-3 species with marginal effect on caspase-7 activation upon ␣B-crystallin knockdown compared with nontargeting control (siNT) (Fig. 2B ). In contrast, knockdown of Bcl2L12 or to a lesser extent of XIAP and Bcl-2 resulted in enhanced of caspase-3 activation and caspase-7 activation ( Fig. 2B ; see Fig. S4 for a second representative experiment using a siRNA pool for Bcl2L12 knockdown) that translated into increased DNA fragmentation levels (Fig. 2C ). Enhanced DNA fragmentation upon ␣B-crystallin knockdown was also observed in U373MG cells, which also show abundant Bcl2L12 and ␣B-crystallin expression (data not shown).
Next, the in vivo oncogenic potential of ␣B-crystallin, Bcl2L12, and EGFRvIII was assessed in the nontumorigenic human glioma cell line LN443, which expresses relatively low levels of endogenous Bcl2L12 and ␣B-crystallin ( Fig. 2D and data not shown). Because of the well described effects of ␣B-crystallin phosphorylation on its diverse biological activities in mammary epithelial cells (14-17), we also examined whether the nonfunctional phosphorylationdeficient (S19E/S45E/S59E, labeled 3XSE) mutant affected the gliomagenic potential of LN443 cells in vivo. Expression levels of ␣B-crystallin proteins were comparable to endogenous ␣B-crystallin found in glioma cell lines, such as LN235, U373MG, and LN215 (data not shown). Orthotopic implantation of LN443 cells with enforced expression of ␣B-crystallin, Bcl2L12, or EGFRvIII resulted in tumor formation and reduced survival, whereas pBabeor 3XSE-transduced LN443 cells failed to produce tumors (Fig. 2  D and E) . Thus, enforced ␣B-crystallin expression in human glioma cells enhances tumorigenic potential, further validating ␣B-crystallin as an oncoprotein in GBM.
␣B-Crystallin Colocalizes With and Binds to Caspase-3 in Vitro and in
Vivo. The prominent effects of ␣B-crystallin on caspase-3 activity prompted detailed localization and immunoprecipitation studies of ␣B-crystallin and caspase-3 species in cortical Ink4a/Arf-deficient astrocytes. First, subcellular fractionation experiments reveal cocompartmentalization of ␣B-crystallin and caspase-3 species in the cytosol of Bcl2L12-expressing astrocytes (Fig. 3A) . Second, GST pull-down assays show specific interaction of recombinant ␣B-crystallin protein with pro-caspase-3 and its cleavage intermediates (Fig. 3B, lanes 11 and 12) , but not with caspase-7 or caspase-9 (Fig.  3B, lanes 9 and 10) . Third, coimmunoprecipitation assays show selective binding of caspase-3, but not caspase-7, to ␣B-crystallin in untreated and, to a lesser extent, in apoptosis-primed Bcl2L12-expressing astrocytes (Fig. 3C) . Finally, deconvolution immunofluorescence microscopy revealed partial colocalization of ␣B-crystallin with pro-caspase-3 and a more extensive colocalization with active caspase-3 in the cytosol of apoptosis-primed cells (Fig.  S5) . Thus, we conclude that ␣B-crystallin binds caspase-3 in astrocytes on an endogenous protein level.
␣B-Crystallin Knockdown Sensitizes Bcl2L12-Expressing Astrocytes Toward Apoptosis in Association with Increased Effector Caspase
Activity. To further assess the functional relevance of ␣B-crystallin in relation to Bcl2L12's cell death activities, we screened four individual siRNA oligonucleotides to identify two with significant knockdown of ␣B-crystallin protein levels in Bcl2L12 V5 -expressing astrocytes (Fig. 4A , siCRYAB-1 and siCRYAB-2). Using these two siRNAs, we examined the effect of ␣B-crystallin knockdown on caspase-3 and caspase-7 activation in response to staurosporine (STS) in control or Bcl2L12-expressing Ink4a/Arf-deficient astro- cytes. As previously reported, Bcl2L12 expression inhibited both caspase-3 and caspase-7 activation (compare siNT time courses in pBabe vs. Bcl2L12; Fig. 4B ). Knockdown of ␣B-crystallin protein in Bcl2L12-expressing astrocytes resulted in specific restoration of caspase-3 activation in response to STS treatment, but had no effect on caspase-7. This translated into sensitization to apoptosis as reflected by increased DNA fragmentation (Fig. 4C) . Because of mitochondrial dysfunction, yet blockage of effector caspase activity, Bcl2L12-expressing Ink4a/Arf-deficient astrocytes showed marked enhancement of necrotic cell death (13) . Expectedly, ␣B-crystallin knockdown reduced necrogenesis as evidenced by a detailed analysis of cellular morphology using transmission electron microscopy (TEM) (Fig. 4 D and E) as a consequence of the aforementioned increase in caspase-3-mediated apoptotic cell death.
Discussion
In this study, we provide functional and biochemical evidence that ␣B-crystallin is a Bcl2L12-induced caspase-3 inhibitor in normal and transformed glial cells. Mechanistically, ␣B-crystallin specifically interacts with and inhibits caspase-3, but not caspase-7, complementing the impact of Bcl2L12 as a direct caspase-7-binding and inhibitory protein on effector caspase activation. The glioma relevance of the Bcl2L12-␣B-crystallin connection is supported by their coexpression in primary GBM samples and their capacity to inhibit apoptosis and enhance tumorigenesis in physiologically relevant systems. These expression and activity profiles support the view that Bcl2L12 and ␣B-crystallin are gliomagenic oncoproteins that cooperate to promote apoptosis resistance in GBM.
␣B-crystallin is a small heat shock protein with known apoptosis regulatory activity as evidenced by its capacity to inhibit programmed cell death associated with death receptor ligation, oxidative stress, chemotherapy, and growth factor withdrawal (14) (15) (16) 18) . Cell-free assays and overexpression studies demonstrated binding to and inhibition of partially processed caspase-3 (14-16). Additionally, ␣B-crystallin is overexpressed in several cancers, including malignant glioma (19) (20) (21) . These previous observations, together with findings of this study in astrocytes and gliomas, strongly support an important oncogenic role for ␣B-crystallin as a downstream effector of Bcl2L12 in cell death signaling in GBM.
In astrocytes, RNAi-mediated depletion of caspase-7 promoted a pronecrotic response (13) and DNA fragmentation was affected by caspase-3 and caspase-7 knockdown (data not shown). In addition, caspase-3 and caspase-7 are activated in parallel, not sequentially downstream of mitochondria in cortical astrocytes (ref. 22 and data not shown). These experimental observations indicate important roles for both effector caspases in apoptosis signaling in astrocytes and, therefore, provide a mechanistic rational for coexpression of Bcl2L12 and ␣B-crystallin in gliomagenesis. In addition, it is intriguing that astrocytes possess a mitochondrial physiology that is somewhat distinct from other cell types. Previous studies have demonstrated that, under normal culture conditions, astrocyte mitochondria exhibit elevated basal mitochondrial potential (23) and oxygen/glucose deprivation fails to induce mitochondrial dysfunction and consequently apoptosis (24) . Significant glycogen reservoirs and inducible glycolysis may guarantee sustained ATP levels that lead to robust steady-state protection of mitochondrial membranes in astrocytes, pointing to effector caspase activation rather than mitochondrial membrane disintegration as a central target for apoptosis inhibition.
Aberrant activation of the PI3K pathway plays a prominent role in GBM pathogenesis. It can be targeted at the level of RTK activation and downstream PI3K signaling, including AKT amplification and foremost loss of the PI3K antagonist PTEN, which is inactivated by loss of heterozygosity in 70% and mutation in 40% of primary GBMs (25) . Notably, ectopic expression of ␣B-crystallin was shown to enhance AKT and ERK1/2 activation, resulting in enhanced proliferative capacity of mammary epithelial cells (17) . It is tempting to speculate that Bcl2L12-induced ␣B-crystallin upregulation acts cooperatively with PI3K pathway hyperactivation to promote glial cell survival and proliferation, suggesting dual roles for the Bcl2L12-␣B-crystallin axis in both apoptosis and mitogenic signaling. Fig. 3 . ␣B-crystallin cocompartmentalizes with and selectively binds to the caspase-3 zymogen and its cleavage intermediates. (A) Bcl2L12 V5 -expressing Ink4a/Arf-deficient astrocytes were treated with STS (1 M) for the indicated periods of time, and cytosolic (C), heavy membranous (HM), and nuclear (N) compartments were prepared as described in Methods. Besides ␣B-crystallin, pro-and active caspase-3 species, the migration positions of cytochrome c P450 reductase (P450R), histon H4 and caspase-3 as membrane, nuclear and cytosolic markers are indicated. (B) Affinity-purified GST and GST-␣B-crystallin fusion proteins (Coommassie-stained gel for purity assessment) were used in GST pull-down experiments to assess for ␣B-crystallin:caspase complex formation. GST or GST-␣B-crystallin proteins were incubated with [ 35 S]labeled in vitro-translated pro-caspase-9 (Casp-9), pro-caspase-7 (Casp-7), pro-caspase-3 (Casp-3), and pro-caspase-3 preincubated with 20 ng of active caspase-8 (Casp-3 proc. ) to induce proteolytic processing of the zymogen. A representative autoradiogram with the migration positions of the caspase-3 pro-enzyme and its active subunits (SS, small subunit; LS, large subunit; LSϩN pep, large subunit plus N-terminal peptide) is shown. (C) Bcl2L12 V5 -expressing astrocytes were treated with STS (1 M) for the indicated periods of time, lysed, and subjected to immunoprecipitation by using monoclonal mouse anti-caspase-7 and rabbit anti-caspase-3 antibodies followed by Western blot analysis under nonreducing conditions for ␣B-crystallin, caspase-3, and caspase-7. The migration positions of IgG and ␣B-crystallin, caspase-7, and caspase-3 are indicated.
Based on (i) the importance of postmitochondrial caspase activation for apoptosis propagation and execution in glial cells, (ii) the selective effects of ␣B-crystallin knockdown on caspase-3 activation (Figs. 2B and 4B ), (iii) the specific interaction with pro and active caspase-3 species on endogenous protein levels (Fig. 3) , and (iv) the selective inhibition of caspase-3, but not caspase-7, activation by recombinant ␣B-crystallin in a cell-free dATP/cytc caspaseactivation assay (14) , we propose that IAP-like caspase-3 neutralization either by preventing the proteolytic processing of the zymogen and/or by direct modulation of the active enzyme is a major route through which ␣B-crystallin exerts its antiapoptotic activity. On the basis of other studies, it is possible that additional mechanisms, such as interaction with Bcl-x S , Bax and p53 to block their translocation to mitochondria (26, 27) and antioxidant activities possibly relating to up-regulation of glucose-6-phosphate dehydrogenase (28, 29) , might further contribute to the antiapoptotic profile of ␣B-crystallin and will require additional study in normal and transformed glial cells.
The convergence of Bcl2L12 and ␣B-crystallin in the inhibition of effector caspase signaling, the frequent and robust overexpression of ␣B-crystallin and Bcl2L12 in GBM, and the proven efficacy of antagonizing effector caspase activity in tumor cells (30) support the development of targeted drugs to block the actions of Bcl2L12/ ␣B-crystallin on effector caspases. The findings of this study predict that enablement of effector caspase function will enhance the responsiveness of GBM to proapoptotic agents such as chemo and radiation therapy.
Methods
Affymetrix Expression Profiling. Total RNA was isolated from subconfluent Ink4a/Arf-deficient astrocytes stably expressing a pBabe control or Bcl2L12 V5 (for retroviral transduction of astrocytes see ref. 13 ) by using TRIzol (Invitrogen) and an RNeasy mini kit (Qiagen). Gene expression profiling was performed on the Affymetrix M430A platform with three independent total RNA preparations. Raw gene expression was analyzed by dChip software (31) . Subcellular Fractionation. Subconfluent Bcl2L12 V5 -expressing astrocytic cultures were stimulated with STS (1 M) for the indicated periods of time, and cytosolic, nuclear, and membrane fractions were prepared by using the Protean Kit (Calbiochem) according to the manufacturer's instructions followed by Western blot analysis using caspase-3, active caspase-3, cytochrome P450 reductase, and histone H4 antibodies (see below).
siRNA Transfection. Subconfluent glioma cells or astrocytes were transfected with siRNA oligonucleotides (Dharmacon) (siRNA nontargeting control; D-001210-01-20), mouse-specific siCRYAB-1 (J-043201-09), siCRYAB-2 (J-043201-10), siCRYAB-3 (J-043201-11), siCRYAB-4 (J-043201-12), human-specific siC-RYAB-1 (J-009743-09), siCRYAB-2 (J-009743-10), siBcl2L12-1 (J-017207-05), siBcl2L12-2 (J-017207-06), siBcl2L12-3 (J-017207-07), siBcl2L12-4 (J-017207-08), siBcl2 (L-003307-00), and siXIAP (L-004098-00) at a concentration of 50 -100 nM by using Oligofectamine (Invitrogen). Cells were treated with STS 48 h after transfection and assayed for DNA fragmentation and caspase maturation.
In Vivo Xenograft Studies. U87MG (1 ϫ 10 5 cells) and LN443 transfectants (1 ϫ 10 6 cells) were injected intracranially into SCID mice (n ϭ 7 for each transfectant). Cells were suspended in HBSS, injected through a burr hole (0.5 mm anterior and 2.0 mm lateral to the Bregma) into the skull of 6-week-old SCID mice that were anesthetized with ketamine (60 mg/kg) and xylazine (7.5 mg/kg), and placed in the stereotactic frame by using ear bars. Cells were injected (total volume 2 l) at a depth of 3.0 mm from the surface of the brain. The scalp was closed with 5.0 silk suture. Animals were followed daily for development of neurological deficits. For pathological analyses, all animals were deeply anesthetized, and their brains were fixed by intracardiac perfusion with 4% paraformaldehyde followed by an additional 12 h of immersion fixation.
Analysis of DNA Fragmentation. Cells were treated with STS (Sigma; 0 -2 M), trypsinized, washed with PBS, and subsequently resuspended in Nicoletti buffer (0.1% Tx-100, 0.1% Na-Citrate, 50 g/ml propidium iodide). Nuclei were analyzed by FACS to quantify sub-G1 DNA content. GST-␣B-Crystallin Protein Preparation, GST Pull-Down Experiments, Immunoprecipitations, and Western Blot Analysis. GST-␣B-crystallin was constructed by PCR amplification of the ␣B-crystallin cDNA (provided by V. Cryns, Northwestern University, Chicago) and cloning of the PCR fragment into pGex4T1. For isolation of recombinant GST and GST-␣B-crystallin proteins, BL21 bacteria (A600nm 0.6 -0.8) were induced with isopropyl ␤-D-thiogalactoside (Sigma) for 4 h at a concentration of 1 M. Cells were washed once with STE buffer [10 mM Tris (pH 8.0), 150 mM NaCl, 1 mM EDTA], lysed, and sonicated in NETN buffer with 1 mM DTT and 5% Sarcosyl. Lysates were cleared by centrifugation (5,000 ϫ g) and incubated with GSH-Sepharose 4B (Amersham) for 2 h at 4°C. Beads were washed five times with NETN buffer and resuspended in IP buffer [0.2% Nonidet P-40, 20 mM Hepes, 142 mM KCl, 1 mM EDTA, complete protease inhibitor mixture (Roche)].
For pull-down experiments, GST fusion proteins were preincubated in IP buffer containing 0.1% BSA to block unspecific binding and subsequently incubated with in vitro-translated, [ 35 S]methionine-labeled proteins overnight at 4°C in IP buffer. Subsequently, beads were washed five times with IP buffer, and associated proteins were analyzed by 4 -12% SDS/PAGE followed by autoradiography. For in vitro processing of caspase-3, 20 ng of recombinant active caspase-8 (BD Biosciences) was added to [ 35 S]radiolabeled caspase-3 for 1 h at 37°C in assay buffer (20 mM Hepes-KOH, 100 mM NaCl, 0,1% CHAPS, 10% sucrose, 1 mM DTT). For immunoprecipitations using monoclonal anti-caspase-3 (Cell Signaling) and anti-caspase-7 antibodies (BD Biosciences), postnuclear supernatants were incubated with mIgG control antibodies coupled to Protein A/G-Sepharose 4B beads (Sigma) and subsequently with anti-caspase-7 and caspased-3 antibodies (1 g) overnight.
Immunoprecipitates were washed three times with IP buffer and subjected to 4 -12% SDS/PAGE followed by Western blot analysis for ␣B-crystallin.
For all Western blot analyses, proteins were separated by 4 -12% SDS/PAGE,
